Targeting gut microbiota as a possible therapy for mastitis

Area of Science:

• Veterinary Medicine
• Microbiology
• Animal Science

Background:

• Mastitis causes significant economic losses in the dairy industry, with antibiotics being the primary treatment.
• Antibiotic overuse leads to resistance, drug residues, and disruption of the gut microbiome, impacting host health.
• Gut microbiota and their metabolites, lipopolysaccharide (LPS) and short-chain fatty acids (SCFAs), are increasingly implicated in mastitis development.

Purpose of the Study:

• To review the role of the gut microbiome and its metabolites in mastitis.
• To explore the potential of probiotics as an alternative treatment for mastitis.

Main Methods:

• Literature review summarizing current research on gut microbiota, metabolites, and mastitis.
• Analysis of the mechanisms by which LPS and SCFAs affect mammary gland inflammation.
• Evaluation of probiotic efficacy in mastitis prevention and treatment.

Main Results:

• Rumen-derived LPS contributes to mammary gland inflammation by increasing permeability.
• SCFAs produced by gut bacteria offer protective effects against mammary inflammation.
• Probiotics show promise as a viable alternative to antibiotics for mastitis management.

Conclusions:

• The gut microbiome significantly influences mastitis development and progression.
• Targeting gut microbiota and their metabolites, potentially through probiotics, offers a novel approach to mastitis control.
• Further research into probiotics can provide a foundation for innovative mastitis prevention and treatment strategies.